Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


For Successful OTC Switch Proposals, A Good Offense Defends Against Doubters

Executive Summary

OTC switch sponsors should identify adversaries early in the application switch process so they can counter arguments that could derail their switch, s consultant advises. Some switches fail because firms target regulatory approval and do little on marketplace performance.


Related Content

Sensitivity To Flu Helped OTC Drug Firms End 2017 With Sales Boost
OTC Switches Face Tougher FDA Evaluations, Less Predictable Process
Chronic Conditions Data Emphasize Need For Additional, Innovative OTCs
GSK's Quesnelle Brings Expertise In Switch To Consulting Arena
Alli Approved OTC For Weight Loss With “Goal Oriented” Indication
In Brief: SmithKline Beecham's Tagamet HB


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts